Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Konkret geht es um den Diabetes-Patienten mit kardiovaskulären Erkrankungen oder Risiken, die Herzinsuffizienz sowie die kardiovaskuläre Primär- und Sekundärprävention. Sind Sie hier schon auf dem neuesten Stand? Unsere Experten beleuchten, wo und warum das bisherige Procedere geändert werden soll und was in der Praxis sinnvoll ist. Holen Sie sich Ihr Update und 2 CME-Punkte beim MMW-Webinar am 24. April von 17.30 bis 19 Uhr. 
Erweiterte Suche
Anmelden
nach oben
Current Diabetes Reports
Erschienen in: Current Diabetes Reports 12/2020

27.11.2020 | COVID-19 | Hospital Management of Diabetes (A Wallia and J Seley, Section Editors) Zur Zeit gratis

Caring for Hospitalized Patients with Diabetes Mellitus, Hyperglycemia, and COVID-19: Bridging the Remaining Knowledge Gaps

verfasst von: Amisha Wallia, Grace Prince, Emilie Touma, Malek El Muayed, Jane Jeffrie Seley

Erschienen in: Current Diabetes Reports | Ausgabe 12/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

This review discusses the interplay between coronavirus disease 2019 (COVID-19, caused by SARS-CoV-2 infection), diabetes mellitus, and hyperglycemia in the hospital setting. There are data emerging about diabetes and hyperglycemia, their prevalence, and potential risks in the setting of SARS-CoV-2 infection and COVID-19.

Recent Findings

It is known that viral infections exert effects on beta cell function and insulin resistance. Therefore, much can be learned about SARS-CoV-2/COVID-19 from examining these known relationships. Such pathophysiological underpinnings may unlock greater understanding as we navigate atypical cases of hyperglycemia, severe insulin resistance, and diabetic ketoacidosis amidst COVID-19. Glycemic outcomes likely have beneficial effects on morbidity and mortality, but this needs to be studied.

Summary

Changes in diabetes-related protocols and new technology can be deployed in the inpatient setting to potentially improve healthcare worker and patient safety; however, one must weigh the risks and benefits of implementation during a pandemic. Ultimately, knowledge and research must be shared at record speed to combat this global crisis.
Literatur
1.
2.
Garg S KL, Whitaker M, et al. Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 – COVID-NET, 14 States, March 1-30, 2020 US Department of Health and Human Services/Centers for Disease Control and Prevention; April 17, 2020.
3.
Muniyappa R, Gubbi S. COVID-19 pandemic, coronaviruses, and diabetes mellitus. Am J Phys Endocrinol Metab. 2020;318:E736–e41.
4.
Yang JK, Feng Y, Yuan MY, Yuan SY, Fu HJ, Wu BY, et al. Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS. Diabet Med. 2006;23:623–8.PubMed
5.
Abstract No 2039-PO. 64th American Diabetes Association Scientific Sessions2004.
6.
Apicella M, Campopiano MC, Mantuano M, Mazoni L, Coppelli A, Del Prato S. COVID-19 in people with diabetes: understanding the reasons for worse outcomes. Lancet Diabetes Endocrinol. 2020;8:782–92.PubMedPubMedCentral
7.••
Holman N, Knighton P, Kar P, et al. Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study. Lancet Diabetes Endocrinol. 2020. This is a population based cohort study of people with diagnosed diabetes in England.
8.
Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med. 2020;180:1.PubMedCentral
9.
Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19). Feb 16, 2020.
10.
Coronavirus disease 2019 (COVID-19) pandemic: increased transmission in the EU/EEA and the UK – seventh update, 2020. Stockholm: ECDC; 2020.
11.
Bode B, Garrett V, Messler J, et al. Glycemic characteristics and clinical outcomes of COVID-19 patients hospitalized in the United States. J Diabetes Sci Technol. 2020;14:813 1932296820924469.PubMedPubMedCentral
12.
Petrilli CM, Jones SA, Yang J, Rajagopalan H, O’Donnell L, Chernyak Y, et al. Factors associated with hospitalization and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. BMJ. 2020;369:m1966.
13.
Simonnet A, Chetboun M, Poissy J, Raverdy V, Noulette J, Duhamel A, et al. High prevalence of obesity in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilation. Obesity (Silver Spring). 2020;28:1195–9.
14.
Tartof SY, Qian L, Hong V, Wei R, Nadjafi RF, Fischer H, Li Z, Shaw SF, Caparosa SL, Nau CL, Saxena T, Rieg GK, Ackerson BK, Sharp AL, Skarbinski J, Naik TK, Murali SB Obesity and mortality among patients diagnosed with COVID-19: results from an integrated health care organization. Ann Intern Med 2020.
15.
Bode B, Garrett V, Messler J, McFarland R, Crowe J, Booth R, et al. Glycemic characteristics and clinical outcomes of COVID-19 patients hospitalized in the United States. J Diabetes Sci Technol. 2020;14(4):813–21.PubMedPubMedCentral
16.
Zhu L, She ZG, Cheng X, Qin JJ, Zhang XJ, Cai J, et al. Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing type 2 diabetes. Cell Metab. 2020;31:1068–1077.e3.PubMedPubMedCentral
17.
Cariou B, Hadjadj S, Wargny M, et al. Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study. Diabetologia. 2020;63:1500–15.PubMedPubMedCentral
18.
Agarwal S, Schechter C, Southern W, Crandall JP, Tomer Y. Preadmission diabetes-specific risk factors for mortality in hospitalized patients with diabetes and coronavirus disease. Diabetes Care. 2019;43:2020.
19.
Chen Y, Yang D, Cheng B, Chen J, Peng A, Yang C, et al. Clinical characteristics and outcomes of patients with diabetes and COVID-19 in association with glucose-lowering medication. Diabetes Care. 2020;43:1399–407.PubMed
20.
Wang S, Ma P, Zhang S, Song S, Wang Z, Ma Y, et al. Fasting blood glucose at admission is an independent predictor for 28-day mortality in patients with COVID-19 without previous diagnosis of diabetes: a multi-centre retrospective study. Diabetologia. 2020;63:2102–11.PubMedPubMedCentral
21.
Kim NYHE, Moon JS, Lee YH, C EU. Acute hyperglycemic crises with coronavirus disease-19: case reports. Diabetes Metab J. 2020;44:349–53.PubMedPubMedCentral
22.
Jie Chee Y, Jia Huey Ng S, Yeoh E. Diabetic ketoacidosis precipitated by Covid-19 in a patient with newly diagnosed diabetes mellitus. Diabetes Res Clin Pract 2020:108166, 164.
23.
Palermo NE, Sadhu AR, McDonnell ME. Diabetic ketoacidosis in COVID-19: unique concerns and considerations. J Clin Endocrinol Metab. 2020;105:2819–29.
24.
Bornstein SR, Rubino F, Khunti K, et al. Practical recommendations for the management of diabetes in patients with COVID-19. Lancet Diabetes Endocrinol. 2020;8:546.PubMedPubMedCentral
25.
Pal R, Banerjee M, Yadav U, Bhattacharjee S. Clinical profile and outcomes in COVID-19 patients with diabetic ketoacidosis: a systematic review of literature. Diabetes Metab Syndr. 2020;14:1563–9.PubMedPubMedCentral
26.
Gianchandani R, Esfandiari NH, Ang L, Iyengar J, Knotts S, Choksi P, et al. Managing hyperglycemia in the COVID-19 inflammatory storm. Diabetes. 2020;69:2048–53.PubMed
27.
Le Roith D, et al. Diabetes mellitus: a fundamental and clinical text. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2003.
28.
Ovalle F. Clinical approach to the patient with diabetes mellitus and very high insulin requirements. Diabetes Res Clin Pract. 2010;90:231–42.PubMed
29.
Illuri VD, Layden BT, Aleppo G. Extreme insulin resistance in critically ill patient with sepsis. Clin Diabetes. 2016;34:158–60.PubMedPubMedCentral
30.
Ettleson MD, Arguello V, Wallia A, Arguelles L, Bernstein RA, Molitch ME. Hyperglycemia and insulin resistance in cardiac arrest patients treated with moderate hypothermia. J Clin Endocrinol Metab. 2014;99:E2010–4.PubMed
31.
Gupta S, Johnson Oakes D, Therasse A, Wallia A, Molitch ME. Extreme insulin resistance following heart transplant. In: Draznin B, editor. Diabetes case studies: real problems, practical solutions. Alexandria: American Diabetes Association; 2015. p. 214–7.
32.
Oo YH, Karam JG, Resta CA. Extreme insulin resistance in a patient with diabetes ketoacidosis and acute myocardial infarction. Case Rep Endocrinol. 2013;2013:520904.PubMedPubMedCentral
33.
Donath MY, Storling J, Berchtold LA, Billestrup N, Mandrup-Poulsen T. Cytokines and beta-cell biology: from concept to clinical translation. Endocr Rev. 2008;29:334–50.PubMed
34.
Pilla SJ, Quan AQ, Germain-Lee EL, Hellmann DB, Mathioudakis NN. Immune-modulating therapy for rheumatologic disease: implications for patients with diabetes. Curr Diab Rep. 2016;16:91.PubMedPubMedCentral
35.
Winter EM, Schrander-van der Meer A, Eustatia-Rutten C, Janssen M. Hydroxychloroquine as a glucose lowering drug. BMJ Case Rep. 2011;bcr0620114393.
36.
37.
Hyoty H, Taylor KW. The role of viruses in human diabetes. Diabetologia. 2002;45:1353–61.PubMed
38.
Roivainen M. Enteroviruses: new findings on the role of enteroviruses in type 1 diabetes. Int J Biochem Cell Biol. 2006;38:721–5.PubMed
39.
Honeyman MC, Stone NL, Harrison LC. T-cell epitopes in type 1 diabetes autoantigen tyrosine phosphatase IA-2: potential for mimicry with rotavirus and other environmental agents. Mol Med. 1998;4:231–9.PubMedPubMedCentral
40.
Honeyman MC, Coulson BS, Stone NL, Gellert SA, Goldwater PN, Steele CE, et al. Association between rotavirus infection and pancreatic islet autoimmunity in children at risk of developing type 1 diabetes. Diabetes. 2000;49:1319–24.PubMed
41.
Sjoholm A. Ketosis-prone type 2 diabetes: a case series. Front Endocrinol. 2019;10:684.
42.
Balasubramanyam A, Nalini R, Hampe CS, Maldonado M. Syndromes of ketosis-prone diabetes mellitus. Endocr Rev. 2008;29:292–302.PubMedPubMedCentral
43.
Yang JK, Lin SS, Ji XJ, Guo LM. Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes. Acta Diabetol. 2010;47:193–9.PubMed
44.
Liu F, Long X, Zhang B, Zhang W, Chen X, Zhang Z. ACE2 expression in pancreas may cause pancreatic damage after SARS-CoV-2 infection. Clin Gastroenterol Hepatol. 2020;18:2128–2130.e2.PubMedPubMedCentral
45.
Tikellis C, Wookey PJ, Candido R, Andrikopoulos S, Thomas MC, Cooper ME. Improved islet morphology after blockade of the renin- angiotensin system in the ZDF rat. Diabetes. 2004;53:989–97.PubMed
46.
Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:271–80.e8.PubMedPubMedCentral
47.
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506.PubMedPubMedCentral
48.
Young BE, Ong SWX, Kalimuddin S, Low JG, Tan SY, Loh J, et al. Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore. Jama. 2020;323:1488–94.PubMedPubMedCentral
49.
Lecube A, Hernandez C, Genesca J, Simo R. Glucose abnormalities in patients with hepatitis C virus infection: epidemiology and pathogenesis. Diabetes Care. 2006;29:1140–9.PubMed
50.
Venetsanaki V, Boutis A, Chrisoulidou A, Papakotoulas P. Diabetes mellitus secondary to treatment with immune checkpoint inhibitors. Curr Oncol. 2019;26:e111–e4.PubMedPubMedCentral
51.
Uhteg K, Jarrett J, Richards M, Howard C, Morehead E, Geahr M, et al. Comparing the analytical performance of three SARS-CoV-2 molecular diagnostic assays. J Clin Virol. 2020;127:104384.PubMedPubMedCentral
52.
Ai T, Yang Z, Hou H, et al. Correlation of chest CT and RT-PCR testing in coronavirus disease 2019 (COVID-19) in China: a report of 1014 cases. Radiology. 2020;296(2):E32–40.PubMed
53.
Hanson K, Caliendo A, Arias C, Englund J, Lee M, Loeb M, et al. Infectious Disease Society of America Guidelines on the Diagnosis of COVID-19. Clin Infect Dis. 2020;ciaa760.
54.
55.
Sardu C, D'Onofrio N, Balestrieri ML, et al. Outcomes in patients with hyperglycemia affected by COVID-19: can we do more on glycemic control? Diabetes Care. 2020;43:1408–15.PubMedPubMedCentral
56.
15. Diabetes Care in the Hospital: Standards of Medical Care in Diabetes-2020. Diabetes Care. 2020;43(Suppl 1):S193–202.
57.
Van den Berghe G, Wilmer A, Hermans G, et al. Intensive insulin therapy in the medical ICU. N Engl J Med. 2006;354:449–61.PubMed
58.
van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, et al. Intensive insulin therapy in critically ill patients. N Engl J Med. 2001;345:1359–67.PubMed
59.
Kumar S, Molitch ME. Use of insulin in the inpatient setting: need for continued use. Curr Diab Rep. 2019;19:64.PubMed
60.
Langouche L, Vanhorebeek I, Vlasselaers D, Vander Perre S, Wouters PJ, Skogstrand K, et al. Intensive insulin therapy protects the endothelium of critically ill patients. J Clin Invest. 2005;115:2277–86.PubMedPubMedCentral
61.
Vanhorebeek I, Langouche L, Van den Berghe G. Glycemic and nonglycemic effects of insulin: how do they contribute to a better outcome of critical illness? Curr Opin Crit Care. 2005;11:304–11.PubMed
62.
Wallia A, Schmidt K, Johnson Oakes D, Pollack T, Welsh N, Kling-Colson S, et al. Glycemic control reduces infections in post-liver transplant patients: results of a prospective, randomized study. J Clin Endocrinol Metab. 2017;102(2):451–9.PubMed
63.
Andersen SK, Gjedsted J, Christiansen C, Tonnesen E. The roles of insulin and hyperglycemia in sepsis pathogenesis. J Leukoc Biol. 2004;75:413–21.PubMed
64.
Deng HP, Chai JK. The effects and mechanisms of insulin on systemic inflammatory response and immune cells in severe trauma, burn injury, and sepsis. Int Immunopharmacol. 2009;9:1251–9.PubMed
65.
66.
Drucker DJ. Coronavirus infections and type 2 diabetes-shared pathways with therapeutic implications. Endocr Rev. 2020;41.
67.•
Korytkowski M, Antinori-Lent K, Drincic A, Hirsch I, McDonnell M, Rushakoff R, et al. A pragmatic approach to inpatient diabetes management during the COVID-19 pandemic. J Clin Endocrinol Metab. 2020;105(9):dgaa342. This is a practical review article on management of those inpatient with hyperglycemia and COVID-19.PubMed
68.
Vellanki P, Rasouli N, Baldwin D, Alexanian S, Anzola I, Urrutia M, et al. Glycaemic efficacy and safety of linagliptin compared to a basal-bolus insulin regimen in patients with type 2 diabetes undergoing non-cardiac surgery: a multicentre randomized clinical trial. Diabetes Obes Metab. 2019;21:837–43.PubMed
69.
Pasquel FJ, Fayfman M, Umpierrez GE. Debate on insulin vs non-insulin use in the hospital setting-is it time to revise the guidelines for the management of inpatient diabetes? Curr Diab Rep. 2019;19:65.PubMed
70.
Lorenzo-Gonzalez C, Atienza-Sanchez E, Reyes-Umpierrez D, et al. Safety and efficacy of ddp4-inhibitors for management of hospitalized general medicine and surgery patients with type 2 diabetes. Endocrine Pract. 2020;26:722–8.
71.
Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. Jama. 2007;298:194–206.PubMed
72.
Mikhail N. Safety of dipeptidyl peptidase 4 inhibitors for treatment of type 2 diabetes. Curr Drug Saf. 2011;6:304–9.PubMed
73.
Willemen MJ, Mantel-Teeuwisse AK, Straus SM, Meyboom RH, Egberts TC, Leufkens HG. Use of dipeptidyl peptidase-4 inhibitors and the reporting of infections: a disproportionality analysis in the World Health Organization VigiBase. Diabetes Care. 2011;34:369–74.PubMedPubMedCentral
74.
Mulvihill EE, Drucker DJ. Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors. Endocr Rev. 2014;35:992–1019.PubMed
75.
Raj VS, Mou H, Smits SL, Dekkers DHW, Müller MA, Dijkman R, et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature. 2013;495:251–4.PubMedPubMedCentral
76.
Tai W, He L, Zhang X, Pu J, Voronin D, Jiang S, et al. Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine. Cell Mol Immunol. 2020;17:613–20.PubMedPubMedCentral
77.
Xu J, Wang J, He M, Han H, Xie W, Wang H, et al. Dipeptidyl peptidase IV (DPP-4) inhibition alleviates pulmonary arterial remodeling in experimental pulmonary hypertension. Lab Investig. 2018;98:1333–46.PubMed
78.
Meyerholz DK, Lambertz AM, McCray PB Jr. Dipeptidyl peptidase 4 distribution in the human respiratory tract: implications for the Middle East respiratory syndrome. Am J Pathol. 2016;186:78–86.PubMedPubMedCentral
79.
Schnapp G, Klein T, Hoevels Y, Bakker RA, Nar H. Comparative analysis of binding kinetics and thermodynamics of dipeptidyl peptidase-4 inhibitors and their relationship to structure. J Med Chem. 2016;59:7466–77.PubMed
80.
Reichetzeder C, von Websky K, Tsuprykov O, Mohagheghi Samarin A, Falke LG, Dwi Putra SE, et al. Head-to-head comparison of structurally unrelated dipeptidyl peptidase 4 inhibitors in the setting of renal ischemia reperfusion injury. Br J Pharmacol. 2017;174:2273–86.PubMedPubMedCentral
81.
Resar R, Pronovost P, Haraden C, Simmonds T, Rainey T, Nolan T. Using a bundle approach to improve ventilator care processes and reduce ventilator-associated pneumonia. Jt Comm J Qual Patient Saf. 2005;31:243–8.PubMed
82.
83.
Schwartz J, King CC, Yen MY. Protecting health care workers during the COVID-19 coronavirus outbreak -lessons from Taiwan’s SARS response. Clin Infect Dis. 2020;53:363.
84.
Yen MY, Lin YE, Lee CH, Ho MS, Huang FY, Chang SC, et al. Taiwan’s traffic control bundle and the elimination of nosocomial severe acute respiratory syndrome among healthcare workers. J Hospital Infection. 2011;77:332–7.
85.
Jones MS, Goley AL, Alexander BE, Keller SB, Caldwell MM, Buse JB. Inpatient transition to virtual care during COVID-19 pandemic. Diabetes Technol Ther. 2020;22:444–8.PubMedPubMedCentral
86.
Rushakoff RJ, Sullivan MM, MacMaster HW, et al. Association between a virtual glucose management service and glycemic control in hospitalized adult patients: an observational study. Ann Intern Med. 2017;166:621–7.PubMed
87.
Aloi J, Bode BW, Ullal J, Chidester P, McFarland RS, Bedingfield AE, et al. Comparison of an electronic glycemic management system versus provider-managed subcutaneous basal bolus insulin therapy in the hospital setting. J Diabetes Sci Technol. 2017;11:12–6.PubMed
88.
89.
90.
Umpierrez GE, Cuervo R, Karabell A, Latif K, Freire AX, Kitabchi AE. Treatment of diabetic ketoacidosis with subcutaneous insulin aspart. Diabetes Care. 2004;27:1873–8.PubMed
91.
Abbott’s Freestyle Libre 14 day system now available in US for hospitalized patients with diabetes during COVID-19 pandemic. Abbott; 2020.
92.
Fact sheet for healthcare providers: use of dexcom continuous glucose monitoring systems during the COVID-19 pandemic. Dexcom 2020.
93.
Wallia A, Umpierrez GE, Rushakoff RJ, Klonoff DC, Rubin DJ, Hill Golden S, et al. Consensus statement on inpatient use of continuous glucose monitoring. J Diabetes Sci Technol. 2017;11:1036–44.PubMedPubMedCentral
94.
Shehav-Zaltzman G, Segal G, Konvalina N, Tirosh A. Remote glucose monitoring of hospitalized, quarantined patients with diabetes and COVID-19. Diabetes Care. 2020;43:e75–e6.PubMedPubMedCentral
95.
Ushigome E, Yamazaki M, Hamaguchi M, Ito T, Matsubara S, Tsuchido Y, et al. Usefulness and safety of remote continuous glucose monitoring for a severe COVID-19 patient with diabetes. Diabetes Technol Ther. 2020.
96.
Reutrakul S, Genco M, Salinas H, et al. Feasibility of inpatient continuous glucose monitoring during the COVID-19 pandemic: early experience. Diabetes Care. 2020.
97.
Singh LG, Satyarengga M, Marcano I, Scott WH, Pinault LF, Feng Z, et al. Reducing inpatient hypoglycemia in the general wards using real-time continuous glucose monitoring: the glucose telemetry system, a randomized clinical trial. Diabetes Care. 2020;43:2736–43.PubMedPubMedCentral
98.
•• Fortmann AL, Spierling Bagsic SR, Talavera L, et al. Glucose as the fifth vital sign: a randomized controlled trial of continuous glucose monitoring in a non-ICU hospital setting. Diabetes Care. 2020;43:2873. This is a randomized controlled trial of real-time continuous glucose monitoring compared to point of care in a non-ICU community hospital setting.
99.
Carayon P, Schoofs Hundt A, Karsh BT, Gurses AP, Alvarado CJ, Smith M, et al. Work system design for patient safety: the SEIPS model. Qual Saf Health Care. 2006;15(Suppl 1):i50–i8.PubMedPubMedCentral
100.
Meyers DC, Durlak JA, Wandersman A. The quality implementation framework: a synthesis of critical steps in the implementation process. Am J Community Psychol. 2012;50:462–80.PubMed
101.
102.
Hoffman T, Nissen K, Krambrich J. Evaluation of a COVID-19 IgM and IgG rapid test; an efficient tool for assessment of past exposure to SARS-CoV-2. 2020;10:1754538.
103.
Esposito K, Nappo F, Marfella R, Giugliano G, Giugliano F, Ciotola M, et al. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation. 2002;106:2067–72.PubMed
104.
105.
Wang XL, Zhang L, Youker K, Zhang MX, Wang J, LeMaire SA, et al. Free fatty acids inhibit insulin signaling-stimulated endothelial nitric oxide synthase activation through upregulating PTEN or inhibiting Akt kinase. Diabetes. 2006;55:2301–10.PubMed
106.
Stefan N, Birkenfeld AL, Schulze MB, Ludwig DS. Obesity and impaired metabolic health in patients with COVID-19. Nat Rev Endocrinol. 2020;16:341–2.PubMedPubMedCentral
107.
Ansorge S, Bank U, Heimburg A, et al. Recent insights into the role of dipeptidyl aminopeptidase IV (DPIV) and aminopeptidase N (APN) families in immune functions. Clin Chem Lab Med. 2009;47:253–61.PubMed
108.
Atkinson MA, Eisenbarth GS, Michels AW. Type 1 diabetes. Lancet. 2014;383:69–82.PubMed
109.
Noble JA, Valdes AM. Genetics of the HLA region in the prediction of type 1 diabetes. Curr Diab Rep. 2011;11:533–42.PubMedPubMedCentral
110.
111.
Lehmann-Werman R, Neiman D, Zemmour H, Moss J, Magenheim J, Vaknin-Dembinsky A, et al. Identification of tissue-specific cell death using methylation patterns of circulating DNA. Proc Natl Acad Sci U S A. 2016;113:E1826–34.PubMedPubMedCentral
112.
Gala-Lopez BL, Neiman D, Kin T, et al. Beta cell death by cell-free DNA and outcome after clinical islet transplantation. Transplantation. 2018;102:978–85.PubMed
113.
Tersey SA, Nelson JB, Fisher MM, Mirmira RG. Measurement of differentially methylated INS DNA species in human serum samples as a biomarker of islet beta cell death. J Vis Exp. 2016;(118):54838. https://​doi.​org/​10.​3791/​54838.
114.
Naylor R, Knight Johnson A, del Gaudio D. Maturity-onset diabetes of the young overview. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews((R)). Seattle: University of Washington, Seattle. University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved; 1993.
Metadaten
Titel
Caring for Hospitalized Patients with Diabetes Mellitus, Hyperglycemia, and COVID-19: Bridging the Remaining Knowledge Gaps
verfasst von
Amisha Wallia
Grace Prince
Emilie Touma
Malek El Muayed
Jane Jeffrie Seley
Publikationsdatum
27.11.2020
Verlag
Springer US
Schlagwort
COVID-19
Erschienen in
Current Diabetes Reports / Ausgabe 12/2020
Print ISSN: 1534-4827
Elektronische ISSN: 1539-0829
DOI
https://doi.org/10.1007/s11892-020-01366-0

Weitere Artikel der Ausgabe 12/2020

Current Diabetes Reports 12/2020 Zur Ausgabe

Genetics (AP Morris, Section Editor)

Genetic Studies of Gestational Diabetes and Glucose Metabolism in Pregnancy

Diabetes Epidemiology (S Albrecht, Section Editors)

Diabetes Risk and Control in Multi-ethnic US Immigrant Populations

Diabetes Epidemiology (S Albrecht, Section Editors)

Use of Machine Learning Approaches in Clinical Epidemiological Research of Diabetes

Macrovascular Complications in Diabetes (VS Aroda and L-S Chang, Section Editors)

Periodic and Intermittent Fasting in Diabetes and Cardiovascular Disease

Psychosocial Aspects (SS Jaser, Section Editor)

Implementation of Technology-Delivered Diabetes Self-care Interventions in Clinical Care: a Narrative Review

Lifestyle Management to Reduce Diabetes/Cardiovascular Risk (B Conway and H Keenan, Section Editors)

Cardiometabolic Morbidity and Mortality with Smoking Cessation, Review of Recommendations for People with Diabetes and Obesity

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

19.04.2024 | Vorhofflimmern | Nachrichten

Parodontalbehandlung verbessert Prognose bei Katheterablation

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Prostatakarzinom: EU initiiert neues Screeningkonzept

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Blasenkarzinom – Biomarker statt Zytologie?

18.04.2024 | Arterielle Hypertonie | Nachrichten

Antihypertensiva schützen auch alte Menschen noch vor Demenz
weitere anzeigen

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise